Christopher R. McEvoy

Dr. Christopher R. McEvoy


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2020 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
CMChristopher R. McEvoy
Christopher R. McEvoy
SFStephen B. Fox
Stephen B. Fox
OPOwen W. J. Prall
Owen W. J. Prall

2 April 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CMChristopher R. McEvoy
Christopher R. McEvoy
HXHuiling Xu
Huiling Xu
KSKortnye Smith
Kortnye Smith
DEDariush Etemadmoghadam
Dariush Etemadmoghadam
HLHuei San Leong
Huei San Leong
OPOwen W.J. Prall
Owen W.J. Prall
BRAF and CRAF are critical components of the MAPK signaling pathway which is activated in many cancer types. In approximately 1% of melanomas, BRAF or CRAF are activated through structural arrangements. We describe here a metastatic melanoma with a GOLGA4-RAF1 fusion and pathogenic variants in CTNNB1 and CDKN2A. Anti-CTLA4/anti-PD1 combination immunotherapy failed to control tumor progression. In the absence of other actionable variants the patient was administered MEK inhibitor therapy on the basis of its potential action against RAF1 fusions. This resulted in a profound and clinically significant response. We demonstrated that GOLGA4-RAF1 expression was associated with ERK activation, elevated expression of the RAS/RAF downstream co-effector ETV5, and a high Ki67 index. These findings provide a rationale for the dramatic response to targeted therapy. This study shows that thorough molecular characterization of treatment-resistant cancers can identify therapeutic targets and personalize management, leading to improved patient outcomes.

20 March 2018 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
CMChristopher R. McEvoy
Christopher R. McEvoy
LKLisa Koe
Lisa Koe
DCDavid Y. Choong
David Y. Choong
HLHuei San Leong
Huei San Leong
HXHuiling Xu
Huiling Xu
SFStephen B. Fox
Stephen B. Fox
Succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC) is a rare RCC subtype that is caused by biallelic mutation of one of the four subunits of the SDH complex (SDHA, B, C, and D) and results in inactivation of the SDH enzyme. Here we describe a case of genetically characterized SDH-deficient RCC caused by biallelic (germline plus somatic) SDHA mutations. SDHA pathogenic variants were detected using comprehensive genomic profiling and SDH absence was subsequently confirmed by immunohistochemistry. Very little is known regarding the genomic context of SDH-deficient RCC. Interestingly we found genomic amplifications commonly observed in RCC but there was an absence of additional variants in common cancer driver genes. Prior to genetic testing a PD-1 inhibitor treatment was administered. However, following the genetic results a succession of tyrosine kinase inhibitors were administered as targeted treatment options and we highlight how the genetic results provide a rationale for their effectiveness. We also describe how the genetic results benefited the patient by empowering him to adopt dietary and lifestyle changes in accordance with knowledge of the mechanisms of SDH-related tumorigenesis.

11 December 2019 in BioTechniques
Verified
Journal Article
Open access
CMChristopher R. McEvoy
Christopher R. McEvoy
TSTimothy Semple
Timothy Semple
BYBhargavi Yellapu
Bhargavi Yellapu
DCDavid Y Choong
David Y Choong
HXHuiling Xu
Huiling Xu
SFStephen B Fox
Stephen B Fox
Tumor DNA sequencing results can have important clinical implications. However, its use is often limited by low DNA input, owing to small tumor biopsy size. To help overcome this limitation we have... Lay abstract The results of tumor DNA sequencing can have important clinical implications. However, limited DNA input owing to small tumor size frequently results in a failed analysis. By incorpora... METHOD SUMMARY To improve the library yield for low DNA input tumor samples subjected to NGS, we adopted a simple modification of the standard KAPA Hyper library preparation procedure. Genomic DNA ...

1 August 2021 in Pathology
Verified
Journal Article
Closed access
OPOwen W.J. Prall
Owen W.J. Prall
NTNiko Thio
Niko Thio
SYSatwica Yerneni
Satwica Yerneni
BKBeena Kumar
Beena Kumar
CMChristopher R. McEvoy
Christopher R. McEvoy

1 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AAArwa Abdelmogod
Arwa Abdelmogod
LPLia Papadopoulos
Lia Papadopoulos
Stephen RiordanStephen Riordan
Stephen Riordan
MWMelvin Wong
Melvin Wong
MWMartin Weltman
Martin Weltman
HBHolly Barker
Holly Barker
Background: Epithelioid haemangioendothelioma (EHE) is an ultra-rare malignant vascular tumour with a prevalence of 1 per 1,000,000. It is typically molecularly characterised by a WWTR1::CAMTA1 gene fusion in approximately 90% of cases, or a YAP1::TFE3 gene fusion in approximately 10% of cases. EHE cases are typically refractory to therapies, and no anticancer agents are reimbursed for EHE in Australia. Methods: We report a cohort of nine EHE cases with comprehensive histologic and molecular profiling from the Walter and Eliza Hall Institute of Medical Research Stafford Fox Rare Cancer Program (WEHI-SFRCP) collated via nation-wide referral to the Australian Rare Cancer (ARC) Portal. The diagnoses of EHE were confirmed by histopathological and immunohistochemical (IHC) examination. Molecular profiling was performed using the TruSight Oncology 500 assay, the TruSight RNA fusion panel, whole genome sequencing (WGS), or whole exome sequencing (WES). Results: Molecular analysis of RNA, DNA or both was possible in seven of nine cases. The WWTR1::CAMTA1 fusion was identified in five cases. The YAP1::TFE3 fusion was identified in one case, demonstrating unique morphology compared to cases with the more common WWTR1::CAMTA1 fusion. All tumours expressed typical endothelial markers CD31, ERG, and CD34 and were negative for pan-cytokeratin. Cases with a WWTR1::CAMTA1 fusion displayed high expression of CAMTA1 and the single case with a YAP1::TFE3 fusion displayed high expression of TFE3. Survival was highly variable and unrelated to molecular profile. Conclusions: This cohort of EHE cases provides molecular and histopathological characterisation and matching clinical information that emphasises the molecular patterns and variable clinical outcomes and adds to our knowledge of this ultra-rare cancer. Such information from multiple studies will advance our understanding, potentially improving treatment options.